Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin-Reference-Cited by-同舟云学术

Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin

Published:2015-11 Issue:11 Volume:21 Page:1039-1053
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Fonseca Eileen,Sander Stephen D.,Hess Gregory P.,Ghosh Sabyasachi

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cross-Cultural Translation into Brazilian Portuguese and Validation of the Oral Anticoagulation Knowledge Tool (AKT-Br);Brazilian Journal of Cardiovascular Surgery;2022

2. Determinants of Prolonged Length of Hospital Stay of Patients with Atrial Fibrillation;Journal of Clinical Medicine;2021-08-20

3. Relationship between predicting bleeding complication in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE‐DAPT) score and mortality among patients with atrial fibrillation undergoing percutaneous coronary intervention;Catheterization and Cardiovascular Interventions;2020-12-09

4. Comparison of hospital length of stay of acute ischemic stroke patients with non-valvular atrial fibrillation started on rivaroxaban or warfarin treatment during hospitalization;Journal of Medical Economics;2020-10-08

5. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States;Journal of Managed Care & Specialty Pharmacy;2018-01